Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent before initiation of any study-related procedures~* Male or female patients aged 18 years or older Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment~* Females must be post menopausal or surgically sterile Self-identified as Hispanic~Exclusion Criteria:~* Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period~* Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment~* Current smokers, including the use of tobacco containing products in the past 1 month of randomization~* Patients requiring dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): None
- Clopidogrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).